Introduction
Vasoactive intestinal peptide (VIP) is a 28-amino acid molecule located in multiple tissues, and capable of exerting a variety of biological effects, including well documented neuroendocrine actions (Abe et al., 1985; Lopez et al., 1989) . One of them is the function of VIP as a physiological PRL-releasing factor of pituitary origin (Abe et al., 1985) .
In the female genital tract the localization of VIP immunoreactive nerves have been described in association with the smooth muscles of blood vessels and the uterus, as well as with the ovarian stroma (Larsson et al., 1977; Alm et al., 1980; Huslhof et al., 1994) . In bovine granulosa cells, immunohistochemical signals for VIP increased in the growing and preovulatory follicles that were coincident with the LH-peak suggesting a role for VIP in the final stages of follicle development and ovulation (Hulshof et al., 1994) . This is in accordance with the findings of Schmidt et al., 1990 , who reported on the increased number of in-vitro ovulations with VIP-perfused ovaries from PMSG primed rats.
Within the ovary, VIP is involved in the regulation of steroidogenic activity, stimulating estradiol and progesterone production in cultured granulosa cells (Davoren and Hsueh, 1985; Ahmed et al., 1986; Parra et al., 2007) . At the same time VIP decreases activity of 20αHSD in these cells, and thus supports the biological activity of progesterone by decreasing the rate of its metabolism to biologically inactive 20α-OH-progesterone (Davoren and Hsueh, 1985) .
In the periphery, the denervation of ovaries during the early luteal phase of the estrus cycle leads to changes in their morphology and impairs steroidogenic activity in pigs (Jana et al., 2005) . Similarly, inhibition of ovarian secretory function and delayed pubertal onset were observed in rats after denervation (Ojeda et al., 1983; Lara et al., 1990; Forneris et al., 2002) .
The alterations in gonadal endocrine function are attributed to the loss of the peptidergic supply of neuronal fibers (Jana et al., 2005; Ojeda et al., 1983; Lara et al., 1990; Forneris et al., 2002) .
The biological action of VIP is mediated through two G-coupled receptors designated as VIPR1 and -2 (respectively, VIPAC-1 and VIPAC-2) (Vaudry et al., 2000) . Both receptors are expressed in the ovaries of different species (Hulshof et al., 1994; Vaccaris et al., 2006; Bao et al., 2000; Cecconi et al., 2004) . Acting through its receptors, VIP dose-dependently increases intracellular cAMP content (Robberecht et al., 1979) and subsequently leads to protein kinase A (PKA) activation, which in turn induces steroidogenesis in granulosa cells.
Nevertheless, the molecular mechanisms by which VIP induces steroidogenesis, and specifically VIP's role in regulating STAR expression, remain unclear. STAR mediates the rate-limiting step in steroidogenesis, the transfer of cholesterol from the outer to the inner mitochondrial membrane, and it is the hormonal regulation of STAR expression and activity that allows tissues to accurately control their steroid production. The cAMP/PKA pathway is the major route in the trophic hormone-stimulated regulation of STAR expression and function, and both known subtypes of PKA (type I and type II) are present in steroidogenic tissues. In mouse Leydig tumor cells, type I PKA is more responsible for Star gene expression, while type II PKA impacts the post-translational regulation of STAR by more readily phosphorylating newly synthesized STAR protein ). Moreover, VIP may affect steroid production through mechanisms downstream of STAR. Recently, a reduction of STAR and 3β-hydroxysteroid dehydrogenase (3βHSD; enzyme converting pregnenolone to progesterone) expression accompanied by decreased serum levels of FSH was demonstrated in young VIP knockout mice (Lacombe et al., 2007) .
These findings, together with the previously reported decrease in gonadal secretory function after neurectomy, strongly suggest an important role for the peptidergic supply from the peripheral neuronal system, and in particular for VIP, in regulating STAR-mediated steroidogenesis in the gonad. In order to address this hypothesis in the present study we used VIP to examine the molecular mechanisms involved in the VIP-mediated regulation of STAR expression in immortalized (KK1) and primary mouse granulosa cells.
Material and Methods

Chemicals and Reagents
N6,2-dibutyryladenosine-3,5-cyclic monophosphate (dbcAMP), phorbol 12-myristate 13-acetate (PMA), H89, pregnant mare serum gonadotropin (PMSG; Gonadotropin), Triton X-100 (TX-100), protease inhibitor cocktail, high glucose (4.5g/l) Dulbecco's modified Eagle's medium (DMEM) and F12 medium and recombinant VIP were purchased from SigmaAldrich (St. Loius, MO).
PKC-specific inhibitor GF-10923X (GFX) was obtained from AG Scientific (San Diego, CA, USA). 8-Piperidinoadenosine-3', 5'-cyclic monophosphate (PIP-cAMP) and N6-mono-tertbutylcarbamoyl-adenosine-3', 5'-cyclic monophosphate (MBC-cAMP) were purchased from BioLog (Bremen, Germany). Tissue culture-grade antibiotics, TRIzol, PCR primers, trypsin EDTA and PBS were purchased from Invitrogen (Carlsbad, CA). The 6-carboxyfluorescein (6-FAM) and 6-carboxytetramethyl-rhodamine (TAMRA) labelled probes ( TaqMan Probes) were from Eurogentec, North America (San Diego, CA). Fetal bovine serum (FBS) was from 
Primary granulosa cells
Primary granulosa cells were obtained from mature, female CD-1 strain mice (Charles River, Wilmington, MA; donated by Dr. GA Cornwall from the Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock). Animals were housed under a constant 12L:12D photoperiod and were allowed free access to food and water. Experiments were carried out in accordance with the principles and procedures described in the NIH Guidelines for Care and Use of Experimental Animals. Mice were killed by cervical dislocation 48h after an ip injection of 8 IU PMSG. A previously described protocol for primary granulosa cell isolation (Salustri et al., 1985) was used. Briefly, the ovaries were removed, trimmed of the surrounding tissue and placed in a HEPES-buffered culture DMEM/F12 (1:1) medium containing heat inactivated 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. The largest follicles were punctured under a dissecting microscope control and cumuli oophori and granulosa cells were released in the medium.
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Ovarian remnants and cumuli oophori were removed and cells were washed twice in the medium with centrifugation steps in between (600 X g, 10 min). After final centrifugation cells were resuspended in culture medium. Cell number and viability were assessed by trypan blue (0.5%) staining and hemocytometer counting. Cells were seeded in 6-well plates at a density of 2x10 6 cells per well and used for experiments 24 hrs later.
Cell culture and Radioimmunoassay
Immortalized KK1 mouse granulosa cells (kindly provided by Dr. Ilpo Huhtaniemi,
Hammersmith Campus, Imperial College London, London UK) and primary granulosa cells were cultured in a humified incubator at 37°C and 5% CO 2 . KK1 cells were maintained in HEPES-buffered DMEM/F12 (1:1) medium containing 10% heat inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. 24hrs prior to stimulation experiments cells were seeded in 6-well plates. For stimulation experiments, cells grown to 70-80% confluency were washed with PBS in order to remove the serum-containing media, which was then replaced by serum-free media containing the agonists. For all experiments cells were stimulated over the time period of 6 hrs. This time point have been chosen based on preliminary experiments in which the highest STAR levels, P-STAR and progesterone output were observed (not shown).
For the experiments were the time course of VIP-mediated PKA activity and CREB and cJUN phosphorylation are presented, 4h time-span has been shown since PKA activity started to decrease after 30 min, reaching basal level after 120 min. This was accompanied by the PcJUN decrease; CREB remained phosphorylated over the entire observation time period.
Finally the medium was collected and stored at -20°C for subsequent radiommunoassay (RIA). The concentration of progesterone was assayed as previously described (Resko et al., 1974) and expressed as pg of progesterone per µg of protein.
Luciferase Assays
The -151/-1 bp fragment of the Star-promoter cloned upstream of the Firefly luciferase reporter gene in the pGL2 basic vector (Promega Corp., Madison, WI) was used for the reporter assay as previously reported (Manna et al., 2002) . 24 hrs before transfection KK1 cells were seeded in 6-well plates and then transfected using FuGENE HD transfection reagent as described in Kowalewski et al., 2009. 1µg of Star-promoter plasmid DNA was used per well. pRL-SV40 plasmid expressing Renilla luciferase driven by CMV immediateearly enhancer and promoter was used to normalize for the transfection efficiency. The activity of the -151/-1 bp Star-promoter construct in response to the VIP and/or dbcAMP 7 treatment was determined after 6 hrs of incubation. The dual-luciferase reporter system was used according to the manufacturer's instructions (Promega). Luminescence was measured using TD-20/20 luminometer (Turner Designers, Sunnyvale, CA). Promoter activity in the samples is reported in relative light units (RLU) and expressed as the ratio of Firefly luciferase luminescence to that of Renilla luciferase.
Protein preparation and Western blot analyses
Following treatments, whole cell lysates were prepared with NET-2 lysis buffer (50 mM TrisHCl [pH 7.4], 300 mM NaCl, 0.05% NP-40; Ishigaki et al., 2001 ) containing 10 µl/ml protease inhibitor cocktail (Sigma Aldrich). Cells were homogenized by sonication with three 10s pulses using a Tekmar TK300 sonic disruptor (Tekmar, Cincinnati, OH). After centrifugation at 10,000xg for 10 min at 4°C the supernatants were used for SDS-PAGE as previously described (Manna et al., 2002) . 
RNA extraction and semi-quantitative Real Time PCR
Semi-quantitative Real Time (TaqMan) PCR was carried out in an automated fluorometer ABI PRISM® 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) according to a previously described protocol (Kowalewski et al., 2006 Relative quantification was performed using the comparative CT method (ΔΔ CT method), according to the instructions of the manufacturer of the ABI PRISM™ 7000 Sequence
Detector and as described in Kowalewski et al., 2006 . Results of the Real Time PCR are expressed as the fold-change in gene expression over the non-treated controls.
Sequences for primers and TaqMan probes used for detection of Star and GAPDH cDNAs were as follows:
Star ( 
PKA activity
The levels of PKA activity after treatment with VIP in KK1 cells were determined with the SignaTECT PKA assay system (Promega) as described in Dyson et al., 2008 .
Data analysis and Statistics
All experiments were independently repeated at least 3 times. Shown are the representative Numerical data were presented as the mean ± standard deviation.
Results
Role of VIP on STAR, 3β-hydroxysteroid dehydrogenase, P-450scc expression and steroid production in granulosa cells.
Using western blot analysis, the expression of both VIP receptors (VIPR1 and VIPR2) was detected in the KK1 cells indicating that these cells can potentially respond to VIP stimulation ( Fig. 2A) .
Treatment with 0.3 dbcAMP also increased Star expression to similar levels, but quantitatively similar results were obtained when VIP was used individually or in cotreatment with cAMP (Fig. 2C) . Similarly, when the proximal -151/-1 bp Star reporter construct was transfected into KK1 cells, promoter activity displayed an approximately 3-fold (p<0.01) increase in response to VIP-treatment when compared with nontreated control (Fig.   2B ). This was comparable to effects observed after stimulation with 0.3 mM dbcAMP individually or in co-treatment (Fig. 2B ). As seen with P450scc, the expression of 3βHSD
was not significantly affected by VIP treatment either individually or in cotreatment with dbcAMP ( Fig. 1C) .
To determine the physiological relevance of the VIP-mediated effects on STAR expression and steroidogenesis, granulosa cells isolated from PMSG-stimulated mice were analyzed using RIA and Real Time PCR (Fig. 3A,B) . Treatment with 1µM VIP for 6 h resulted in a 2.8-fold (p<0.01) increase in Star mRNA expression over untreated cells, and this increase closely resembled the induction seen after stimulation with 1mM dbcAMP (2.1-fold increase; p<0.01) (Fig. 3B) . Accumulation of progesterone in the media was elevated by 8.9-(p<0.01) and 18.6-fold (p<0.01) by VIP and dbcAMP, respectively, when compared with controls, further confirming the involvement of VIP in the STAR-mediated steroidogenic response.
These findings demonstrate that VIP is capable of strongly activating Star gene expression at levels similar to those observed with cAMP analog treatment. Notably, the VIP-mediated increase in Star mRNA did not correlate with a matched increase in steroid production as we observed in the group treated with dbcAMP.
Effects of VIP on specific PKA activity.
The levels of PKA activity following VIP stimulation were evaluated. To do this we examined the effect of 1 µM VIP on PKA activity in KK1 cells at different time points over a period of 4 h (Fig. 4A) . PKA activity at the initial time point was very low; it rose steeply within the first 3 minutes, reaching a maximum after 15 minutes. After 30 minutes the PKA activity started to decrease reaching very low or basal values by 120 and 240 minutes. Cells treated with 1.0 mM dbcAMP were used as a positive control, and consistently yielded high PKA activity, even after 4-6 h of incubation. As a negative control for the assay, PKA activity was quenched with the PKA inhibitor H89.
VIP-mediated effects on CREB and cJUN expression.
Since VIP effectively induced Star gene and protein expression, it seemed plausible that transcription factors known to regulate Star transcription could be regulated by VIP. Using
Western blot analyses, we examined the expression and phosphorylation status of two prominent and well studied Star promoter activators that are sensitive to PKA: cJUN and CREB. KK1 cells were stimulated with 1µM VIP and changes in the phosphorylation status of both transcription factors were examined at different time points over a period of 4 h (Fig.   4B ). Both factors were readily detected in unstimulated cells, with no changes in total protein expression observed during the time course of the experiment. The relative abundance of phospho-CREB and phospho-cJUN were strongly induced following treatment with 1µM VIP when compared to total CREB and cJUN. The phosphorylation of cJUN (4-fold; p<0.01) occurred after 5 minutes, reached a maximum (4.9-fold; p<0.01) after 30 minutes of VIP stimulation, and started to decline afterwards, dropping to basal levels by 240 minutes (p>0.05) (Fig. 4B ). The phosphorylation of CREB was significantly increased (2.6-fold; p<0.01) by 10 minutes, reaching a maximum (up to 5-fold) within 15 to 60 minutes and remaining high for the duration of the time course (Fig. 4B) . Having seen the rapid phosphorylation of cJUN in response to VIP treatment, we assessed the functional activity of cJUN in response to these treatments. KK1 cells were transfected with a pathway-specific cJUN trans-reporting system. Cells were stimulated with 1mM dbcAMP and 1µM VIP either individually or in co-treatment for 6 h. A 1.55-(p>0.05) and 2.53-fold (p<0.01) increase in luciferase activity, relative to untreated controls, were observed in response to dbcAMP and VIP, respectively. A further, up to 3.12-fold increase (p<0.01), was detected in the groups treated with a combination of VIP and dbcAMP (Fig. 4C) . These results reflect how VIPmediated activation of STAR expression and steroidogenesis could be coordinated by the targeted activation of the Star promoter and its transcriptional machinery.
Role of PKA and PKC in VIP-mediated STAR expression and steroidogenesis.
To more specifically evaluate the signalling events in VIP-mediated steroidogenesis, we wished to assess the independent roles of the PKA and PKC pathways as they function downstream of VIP, and to know how these pathways then affect STAR expression. To examine PKA, KK1 cells were treated with 0.3 mM dbcAMP and 1µM of VIP alone and in co-treatment. Cells pre-treated for 30 min with the specific inhibitor of PKA, H89 (20µM) markedly diminished (p<0.01) all responses (Fig. 5A ,B,C). In order to elucidate the role of the PKC pathway in VIP-mediated steroidogenesis, StAR expression in response to the PKC activator, phorbol 12-myristate 13-acetate (PMA) was determined and compared with VIP.
Stimulation of KK1 cells with 20 nM PMA resulted in a significant (p<0.01) increase in Star-mRNA (6.3-fold; p<0.01) and protein (4.45-fold; p<0.01) expression (Fig. 6A,B) . No P-STAR and low steroid levels were observed in response to PMA (Fig. 76,C (Fig. 6B,C) . While VIP paired with PMA did result in increased P-STAR relative to the control and either compound alone, their combined use generated less P-STAR than 0.3 mM dbcAMP. Quantitatively similar levels of Star mRNA were observed in response to VIP and PMA (Fig. 6A) . The inhibition of the PKC pathway by the specific inhibitor GF-109203X (GFX; 20 µM) markedly reduced the response to both PMA and VIP (Fig. 6 ). These findings demonstrate that signalling from not only PKA, but also PKC can transduce signals in response to VIP, and that these pathways converge to regulate STAR expression and function, and hence the steroidogenic response in these cells.
The induction of STAR phosphorylation in response to vasoactive intestinal peptide (VIP);
differential activation of PKA.
The activation of PKC has been shown to result in the effective transcription and translation of STAR. However, a further activation of the PKA pathway is required to effectively phosphorylate STAR and induce steroid production (Jo, et al., 2005) . On the basis of this phenomenon, using specific analogs of cAMP to preferentially activate either type I or type II PKA, we were recently able to show that type I PKA is more involved in Star gene expression, while the activation of type II PKA is essential for efficient phosphorylation of STAR and consequently production of steroids concentrations previously demonstrated to preferentially activate type II PKA ); neither STAR expression nor an increase in steroid production were observed in response to this treatment (Fig. 7B,C) . As a positive control KK1 cells were treated with 0.3 mM dbcAMP (Fig. 7) . To demonstrate the specific activation of type II PKA, 20µM PMA was used either alone or in conjunction with type II analogs. As expected type II PKA activators resulted in the phosphorylation of PMA-induced STAR (Fig. 7B ). As before, little 13 or no STAR phosphorylation was observed when KK1 cells were treated with up to 1.0 µM VIP. However, the addition of type II analogs resulted in phosphorylation of STAR to levels comparable with those observed in the group treated with PMA and type II activators and stimulated as much progesterone as in the cells treated with 0.3 mM cAMP (Fig. 7B,C) . In this context the cAMP signalling from VIP appears to most directly affect type I PKA activity.
Discussion
The role of neuropeptides, and in particular VIP, in regulating gonadal steroidogenic activity has been widely discussed (Larsson et al., 1977; Alm et al., 1980; Davoren and Hsueh, 1985; El-Gehani et al., 1998a; Hulshof et al., 1994; Jana et al., 2005) . All previous observations point towards an important role of peptidergic supply at the level of the peripheral neuronal system in regulating reproductive function. However, VIP is also capable of acting directly on the steroidogenic tissues of the gonads, where it effectively stimulates steroid production (Davoren and Hsueh, 1985; Ahmed et al., 1986; El-Gehani et al., 1998b; Parra et al., 2007) .
Even though there are some indications that VIP could be involved in STAR-mediated steroidogenesis (Lacombe et al., 2007) , the role of VIP in this context has not been closely studied, much less fully elucidated. The present study extends our knowledge of the molecular regulatory mechanisms in which VIP acts to increase the steroidogenic response by driving STAR expression and function in immortalized mouse KK1 and primary mouse granulosa cells.
Fitting with previous studies, we observed VIP to consistently induce steroidogenesis in granulosa cells in a concentration-dependent manner ( Fig. 1B; Fig. 3A ). This is in accordance with results reported by Davoren and Hsueh, 1985 , where VIP dose-dependently stimulated progesterone and estrogen production in rat granulosa cells. Similarly, Parra et al., 1985 observed increased steroid release from cultured ovarian tissue in response to stimulation with VIP. In addition, our current data demonstrate that VIP is capable of potently increasing the expression of STAR and steroid production both in KK1 and freshly isolated granulosa cells.
Notably, VIP did not seem to regulate the enzymatic availability of P450scc and 3βHSD, since the expression of both enzymes were not significantly affected in response to VIP (Fig.   1C ).
VIP acts through its two receptors, both of which are expressed in granulosa cells in vivo (Barberi et al., 2007 ) and which we also observed here in KK1 cells (Fig. 1A) . As members of the secretin family of receptors, VIPR1 and VIPR2 are conventionally thought to activate adenylate cyclase, and the activation of the VIPR leads to a dose-dependent increase in the intracellular cAMP content (Robberecht et al., 1979) that is potentially capable of increasing the PKA activity. Based on this, it is presumable that VIP would stimulate STAR expression via the PKA pathway. In our study, VIP proved to be a very potent activator of PKA.
Maximal catalytic activity of the enzyme was reached within 15 minutes (Fig. 4A ). During this time CREB and cJUN, two prominent factors in the Star transcriptional machinery were strongly phosphorylated (Fig. 4B) , reflecting the targeted activation of Star gene expression in response to the peptidergic stimulation. This observation may mirror the pituitary, where previously published observations showed that VIP could strongly induce the phosphorylation of CREB (Fernandez et al., 2005) . This data pairs well with the results from our real time PCR and promoter activity data indicating that incubation of KK1 and primary granulosa cells with VIP strongly induced Star promoter activity, resulting in mRNA levels comparable to those observed in response to dbcAMP. This suggests that cAMP signalling from VIP strongly enhances STAR expression at the transcriptional level.
The activation of the PKA pathway is unquestionably the major signalling route in STARmediated steroidogenesis. In this regard, the ability of VIP to activate the PKA pathway was a requirement for increases in STAR and steroidogenesis, since H89 diminished all VIP effects (Fig. 5) . While it was clear that cAMP transduces signals from the activated VIPR in these cells, we noticed that STAR protein expression and steroidogenesis from VIP treatment lagged behind the transcription of Star. Notably, the lower doses of VIP consistently produced elevated Star promoter activity and Star mRNA levels that matched our dbcAMP controls, but STAR protein expression, phosphorylation and steroid production were typically lower even as VIP concentrations increased. This closely resembled the phenomenon described by Jo et al., 2005 regarding how PKC could regulate Star expression. Given that PKC and other signalling pathways can also be activated by VIP, we investigated the potential role of the PKC pathway in VIP mediated steroidogenesis. Blocking of PKC activity resulted in a significant reduction of the VIP response (Fig. 6 ), suggesting that PKC may also serve downstream of VIP. Additionally, the increased STAR expression and enhanced steroidogenic output in response to the combined treatment with VIP and PMA demonstrate an important role for PKC activity in mediating VIP effects. Thus, it appears that the cooperation between different signalling pathways is involved in the regulatory events in the VIP-mediated effects on STAR function and gonadal steroid production.
Given that PKA activity was dramatically increased in these cells in response to VIP alone, and that Star was being actively synthesized, it was perplexing to observe reduced levels of steroidogenesis. Specifically, increased levels of P-STAR and progesterone were observed when VIP was used in concert with dbcAMP. Thus VIP by itself, although capable of increasing STAR protein, did not permit effective phosphorylation of STAR, and resulted in lower steroidogenic output when compared to dbcAMP stimulation (Fig. 1B) . This suggests that VIP requires further cAMP-mediated activation of PKA to produce a full response.
Recently, we were able to illustrate how the different isoforms of PKA act in regulating STAR function with Type I PKA being more responsible for Star gene expression and Type II PKA appearing to be much more efficient at phosphorylating STAR.
In view of these earlier reports, an interesting finding in our current study is the observations that the effects of VIP on STAR expression in granulosa cells may predominantly result from the preferential activation of type I PKA. We observed that VIPinduced Star transcription and translation was supplemented by the additional activation of Type II PKA, which efficiently phosphorylated and hence activated STAR and consequently enhanced steroid production (Fig. 7) . Similarly, in the experiments where PMA was used alone to activate PKC and induce Star expression, VIP was demonstrated to be a very potent activator of Star transcription. However, even when PMA and VIP were used together, P-STAR levels were still lower than what we observed using dbcAMP, suggesting that some aspect of PKA signalling was still limited. Since the additional activation of type II PKA appeared sufficient to allow a full steroidogenic response to VIP treatment, we predict that VIPR cAMP signals are predominantly transduced through Type I PKA. Observations, such as the rapid and strong phosphorylation of CREB and cJUN in response to VIP make our hypothesis even more probable, since we have previously observed the phosphorylation of those two factors by type I PKA in MA10 mouse Leydig tumor cells ).
The steroidogenic effects of VIP, though weaker than those seen with cAMP, could play a supportive role in trophic hormone regulated (e.g. FSH, LH) ovarian endocrine function. This becomes more plausible if the increased VIP immunoreactivity that has been seen in the bovine ovary immediately prior and during the LH-peak (Huslhof et al., 1994 ) is taken into account. Similarly the VIP concentration in the rat ovary is cycle stage dependent with the highest levels seen during dioestrus (Parra et al., 2007) .
In conclusion and as summarized in Fig. 8 , our findings demonstrate that the capacity for VIP to induce steroidogenesis is mediated by PKA and PKC through STAR, and that these pathways appear to converge to regulate the levels of Star transcription and translation. 1mM dbcAMP for additional 6 h and luciferase activity in the cell lysate was determined.
Lower case letters are used to designate groups that differ significantly (p < 0.01) 
